Ora Secures Vistria Group Investment for Global Growth in Ophthalmic Research

Ora, a leading global contract research organization (CRO) specializing in ophthalmic research, has announced a strategic recapitalization by The Vistria Group, a middle-market private investment firm focused on delivering financial returns and societal impact. “The Vistria Group’s investment underscores their…

Read MoreOra Secures Vistria Group Investment for Global Growth in Ophthalmic Research

AscellaHealth’s Q2 2024 Specialty & Rare Pipeline Digest™ Shows Rising Specialty Pharmaceuticals Demand

AscellaHealth, a global partner specializing in end-to-end solutions for life sciences and healthcare companies aimed at improving the quality of life for patients with complex, chronic conditions, has launched its latest edition of the Specialty & Rare Pipeline Digest™. This…

Read MoreAscellaHealth’s Q2 2024 Specialty & Rare Pipeline Digest™ Shows Rising Specialty Pharmaceuticals Demand

Vabysmo by Genentech Demonstrates Long-Term Effectiveness and Safety in Diabetic Macular Edema Study

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), unveiled new four-year findings from the RHONE-X extension study today. The study successfully met all primary endpoints, underscoring the well-tolerated nature of Vabysmo® (faricimab-svoa) in individuals with diabetic…

Read MoreVabysmo by Genentech Demonstrates Long-Term Effectiveness and Safety in Diabetic Macular Edema Study

Galvani Bioelectronics Advances Therapy Platform, Appoints New Chief Medical Officer

Galvani Bioelectronics, a clinical-stage therapeutics company resulting from a partnership between GSK and Verily Life Sciences, has initiated recruitment for the randomized, controlled phase of a clinical feasibility study targeting patients with Rheumatoid Arthritis (RA). This advancement follows FDA approval,…

Read MoreGalvani Bioelectronics Advances Therapy Platform, Appoints New Chief Medical Officer

Study Finds No Survival Difference Between Mismatched and Matched Unrelated Donors

Research findings published today in the peer-reviewed Journal of Clinical Oncology by NMDP℠ and CIBMTR® (Center for International Blood and Marrow Transplant Research®) indicate that there is no significant difference in overall survival (OS) for patients with blood cancer undergoing…

Read MoreStudy Finds No Survival Difference Between Mismatched and Matched Unrelated Donors

Sensorion Reports Positive Secondary Endpoints in SENS-401 Phase 2a Trial for Hearing Loss Preservation

Sensorion (FR0012596468 – ALSEN), a pioneering biotechnology company specializing in hearing loss disorders, has unveiled new positive findings from its SENS-401 Phase 2a clinical trial. The data, focusing on the preservation of residual hearing following cochlear implantation in adult patients,…

Read MoreSensorion Reports Positive Secondary Endpoints in SENS-401 Phase 2a Trial for Hearing Loss Preservation